SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-47277"
 

Search: onr:"swepub:oai:DiVA.org:liu-47277" > Pegylated interfero...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Dalgard, Olavand Infectious Disease Department, Ullevål University Hospital, Oslo, Norway and Medical Department, Aker University Hospital, Oslo, Norway (author)

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2007-11-01
  • Ovid Technologies (Wolters Kluwer Health),2008
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-47277
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47277URI
  • https://doi.org/10.1002/hep.21975DOI
  • https://lup.lub.lu.se/record/1200277URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428 treatment-naïve HCV RNA–positive patients with genotype 2 or 3 were enrolled. Patients with RVR were randomized to 14 (group A) or 24 (group B) weeks of treatment. Patients were treated with pegylated interferon α-2b (1.5 μg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily. The noninferiority margin was set to be 10% between the two groups with a one-sided 2.5% significance level. RVR was obtained in 302 of 428 (71%), and 298 of these were randomized to group A (n = 148) or group B (n = 150). In the intention-to-treat analysis, SVR rates were 120 of 148 (81.1%) in group A and 136 of 150 (90.7%) in group B (difference, 9.6%; 95% confidence interval, 1.7-17.7). Among patients with an HCV RNA test 24 weeks after the end of treatment, 120 of 139 (86.3%) patients in group A achieved SVR compared with 136 of 146 (93.2%) in group B (difference, 6.9%; 95% confidence interval, −0.1 to +13.9). Conclusion: We cannot formally claim that 14 weeks of treatment is noninferior to 24 weeks of treatment. However, the SVR rate after 14 weeks of treatment is high, and although longer treatment may give slightly better SVR, we believe economical savings and fewer side effects make it rational to treat patients with genotype 2 or 3 and RVR for only 14 weeks.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bjøro, KristianMedical Department, Rikshospitalet, Oslo, Norway (author)
  • Ring-Larsen, HelmerLiver Unit, Rigshospitalet, Copenhagen, Denmark and Faculty of Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark (author)
  • Bjornsson, EinarDepartment of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden (author)
  • Holberg-Petersen, MonaDepartment of Microbiology, Ullevål University Hospital, Oslo, Norway (author)
  • Skovlund, EvaSchool of Pharmacy, University of Oslo, Oslo, Norway (author)
  • Reichard, OlleKarolinska University Hospital, Stockholm, Sweden (author)
  • Myrvang, BjørnInfectious Disease Department, Ullevål University Hospital, Oslo, Norway (author)
  • Sundelöf, BoMedical Department, Gävle Hospital, Gävle, Sweden (author)
  • Ritland, StåleMedical Department, Buskerud University Hospital, Drammen, Norway (author)
  • Hellum, KjellMedical Department, Akershus University Hospital, Nordbyhagen, Norway (author)
  • Frydén, ArilLinköpings universitet,Infektionsmedicin,Hälsouniversitetet(Swepub:liu)arifr37 (author)
  • Florholmen, JonMedical Department, Tromsø University Hospital, Tromsø, Norway (author)
  • Verbaan, HansLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Medical Department, Malmö University Hospital, Malmö, Sweden(Swepub:lu)medf-hve (author)
  • and Infectious Disease Department, Ullevål University Hospital, Oslo, Norway and Medical Department, Aker University Hospital, Oslo, NorwayMedical Department, Rikshospitalet, Oslo, Norway (creator_code:org_t)

Related titles

  • In:Hepatology: Ovid Technologies (Wolters Kluwer Health)47:1, s. 35-420270-91391527-3350

Internet link

Find in a library

  • Hepatology (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view